Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Influenza DNA vaccine: Phase I expanded

VICL expanded an ongoing double-blind, placebo-controlled Phase I trial to evaluate Vaxfectin-formulated

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE